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In recent decades cancer survivorship has steadily increased; however, 
the adverse side effects associated with chemotherapy treatment can diminish 
a patient’s overall quality of life.  One of the most effective and widely used 
chemotherapeutic agents is doxorubicin (DOX).  Though highly effective, its 
use is limited by a dose-dependent cardiotoxicity.  While it is known that 
exercise preconditioning with endurance training models provide a 
cardioprotective effect to DOX treatment, little focus has been placed on the 
effects of a resistance training (RT) model on DOX-induced cardiac 
dysfunction.   
The purpose of the study was to determine the effects of a 12-week RT 
model on DOX-induced cardiac dysfunction to determine if any 
cardioprotective effects are a result of a reduction in lipid peroxidation and to 
determine if any cardioprotective effects are a result of a preservation of the 
cardiac myosin heavy chain (MHC) isoform distribution.   
Ten-week-old male Sprague-Dawley rats were randomly selected to 
undergo 12 weeks of RT or remain sedentary (SED).  Twenty-four hours 
following the completion of the exercise training or sedentary period, animals 
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received a 12.5 mg/kg bolus intraperitoneal injection of DOX or a bolus 
intraperitoneal injection of 0.9% saline.  Five days following injection, animals 
were sacrificed.  Cardiac function was assessed both in vivo and ex vivo and 
the left ventricle tissue was used to assess lipid peroxidation, as measured by 
malondialdehyde (MDA) + 4-hydroxyalkenal (HAE) and percentage of β-MHC.   
The DOX treatment induced cardiac dysfunction when measured both 
in vivo and ex vivo.  The RT provided a cardioprotective effect, evident by 
significant increases in end systolic pressure, left ventricular developed 
pressure, and the maximal rate of developed pressure.  No significant 
difference existed between RT+DOX and SED+DOX in lipid peroxidation; 
however, RT did attenuate the α- to β-MHC shift that occurs with DOX 
treatment.   
These data suggest that 12 weeks of the RT model used provided 
cardioprotection against DOX-induced cardiac dysfunction and may be a result 
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Cancer is one of the leading causes of morbidity and mortality 
throughout the world.  In 2015, it is estimated that there will be more than 1.6 
million new cases of cancer diagnosed in the United States (Siegel, Miller, & 
Jemal, 2015).  In addition, it is estimated that more than 580,000 people are 
expected to succumb to the disease in 2015, thus statistically making cancer 
the second most common cause of death in the United States.  The risk of 
dying from cancer has steadily declined over the past two decades, including a 
22% decrease between 1991 and 2011 (Siegel et al., 2015).  Increased 
survival rates for cancer patients are due, in part, to progressive methods of 
prevention, detection, and treatment options available to patients.  Increased 
survival rates have led to a greater emphasis on improving overall quality of 
life in cancer survivors, with a particular focus on reducing or attenuating 
treatment-related side effects. 
 A Food and Drug Administration approved chemotherapeutic agent 
successful in the treatment of a variety of cancers is doxorubicin (DOX), 
clinically known as Adriamycin®.  Clinicians began prescribing DOX to cancer 
patients as a chemotherapy treatment in 1974.  Since then, it has been used 
to treat a variety of malignancies, both solid and hematological (Weiss, 1992).  
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While substantially effective at treating cancer, the implementation of DOX into 
routine cancer treatment regimens has been limited due to its known 
detrimental cardiotoxicity.  A well-characterized side effect of DOX is its dose-
dependent cardiotoxicity, which can be manifested as cardiac dysrhythmias, 
contractile dysfunction, or even congestive heart failure (Steinherz, Steinherz, 
Tan, Heller, & Murphy, 1991).  Mechanistic actions of DOX that have been 
reported to induce cardiotoxicity include interference with deoxyribonucleic 
acid (DNA) strand separation during replication (Bachur et al., 1992), induction 
of apoptosis (Wonders, Hydock, Greufe, Schneider, & Hayward, 2009), and 
excess generation of reactive oxygen species (ROS) (Minotti, Menna, 
Salvatorelli, Cairo, & Gianni, 2004) 
 Aside from examining ways to prevent, diagnose, and treat cancer, 
researchers have diligently investigated interventions aimed at the reduction or 
attenuation of burdensome side effects commonly accompanying cancer 
treatment.  Purported to counteract many of the transient and chronic effects 
associated with cancer treatments, the role of regular exercise in the 
prevention and treatment of cancer has been the focus of much clinical 
research over the past 15 years.  
 Studies have suggested that exercise preconditioning may reduce 
DOX-induced cardiotoxicity following treatment (Hydock, Lien, Jensen, 
Schneider, & Hayward, 2011; Hydock, Lien, Schneider, & Hayward, 2008; 
Jensen, Lien, Hydock, Schneider, & Hayward, 2013).  However, not fully 
understood are the mechanisms involved with the induction of exercise-
mediated cardioprotection.  Exercise-induced cardioprotection against DOX 
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toxicity may be explained by upregulation of heat shock proteins (HSP) 
(Chicco, Schneider, & Hayward, 2005), downregulation of pro-apoptotic 
pathways (Wonders et al., 2009), increased antioxidant enzymes (Ascensão et 
al., 2005; Ashrafi, Roshan, & Mahjoub, 2012; Chicco, Hydock, Schneider, & 
Hayward, 2006; Kanter, Hamlin, Unverferth, Davis, & Merola, 1985), 
decreased lipid peroxidation (Marques-Alexio et al., 2014; Wonders, Hydock, 
Schneider, & Hayward, 2008), decreased cardiac DOX accumulation (Jensen 
et al., 2013), and/or by increasing the expression of multi-drug resistance 
protein (Krause et al., 2007). 
 Although a substantial amount of research has focused on the effects of 
endurance training, little attention has been placed on the effects of resistance 
training (RT) on DOX-induced cardiotoxicity.  Cancer rehabilitation programs 
have begun to incorporate RT due to the fact that this type of training can 
result in significant improvements in muscular strength, aerobic capacity, and 
quality of life (Schwartz & Winters-Stone, 2009; Segal et al., 2003; Winters-
Stone et al., 2012).  Additionally, RT has been utilized as a rehabilitative 
therapy for heart failure, which may accompany DOX treatment, to counteract 
damaging peripheral side effects and improve quality of life (Alves, Nunes, 
Stefani, & Dal Lago, 2014).  To our knowledge, no studies have been 
conducted which examine the effects of RT on DOX-induced cardiotoxicity.  
Statement of Purpose 
 The purpose of this study was threefold: (a) to examine the effects of 
chronic RT prior to the administration of DOX on in vivo and ex vivo cardiac 
function in male Sprague Dawley rats, (b) to determine if any cardioprotective 
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effects are a result of a reduction in lipid peroxidation, and (c) to determine if 
any cardioprotective effects are a result of a preservation of the cardiac 
myosin heavy chain (MHC) isoform distribution. 
Research Hypotheses 
H1 Resistance training will provide protection against the cardiac 
dysfunction associated with doxorubicin treatment. 
 
H2 Resistance training will mitigate the increase in cardiac lipid 
peroxidation associated with doxorubicin treatment. 
 
H3 Resistance training will attenuate the cardiac α- to β-myosin 












Abbreviations Used in This Study 
 




ATP adenosine triphosphate 
CA2+ calcium 
CAT catalase 
CHF chronic heart failure 
CuSOD copper zinc superoxide
 dismulase 
DNA deoxyribonucleic acid 
DOX doxorubicin 
+dP/dt maximum rate of 
 developed pressure 
-dP/dt minimum rate of 
 developed pressure 
EDP end diastolic pressure 
EF ejection fraction 
ESP end systolic pressure 
FS fractional shortening 
GPX glutathione peroxidase 
HSP heat shock protein 
H2O2 hydrogen peroxide 
i.p. intraperitoneal 
LV left ventricular 
LVDd LV end diastolic 
 diameter 
LVDP LV developed pressure 
LVDPd LVDP during diastole 




MHC myosin heavy chain 
MnSOD manganese superoxide 
 dismutase 
MPTP mitochondrial permeability 
 transitional pore 
NADH nicotinamide adenine 
 dinucleotide 
NO nitric oxide 
O2 oxygen 
O2•
- superoxide anion 
OH hydroxyl radical 
ONOO- peroxynitrite 
PWd posterior wall thickness 
 during diastole 
PWs posterior wall thickness 
 during systole 
RNS reactive nitrogen species 
ROS reactive oxygen species 
RYR ryanodine receptor 
SERCA2 sarcoendoplasmic 
 reticulum ATPase 2 
SED sedentary 
SOD superoxide dismutase 
SWd septal wall thickness 
 during diastole 
SWs septal wall thickness 




Definition of Terms 
Apoptosis. Programmed cell death. 
Cardiomyopathy. Disease of the heart when the myocardium becomes 
enlarged, thick, or rigid and can lead to heart failure. 
Cardioprotection. Adaptations in the heart that provide increased 
tolerance to ischem or chemical-induced injury.  
Cardiotoxocity. Damage to the heart from cytotoxic drugs. 
Cytochrome c. A small essential protein located at outside of inner 
mitochondria membrane attaching to cardiolipin, transports electrons (between 
complex III and IV) during aerobic energy production, and initiates intrinsic 
apoptosis pathway.  
Dilated cardiomyopathy. A pathological condition of the heart where 
the chamber enlarges and the walls thin, interfering with ejection of blood from 
the heart. 
Doxorubicin. Chemotherapy agent approved by the Food and Drug 
Administration for the treatment of a variety of cancers including non-
Hodgkin’s lymphoma, acute leukemia, and multiple myeloma and cancers of 
the breast, adrenal cortex, endometrium, lung, and ovary.  
Echocardiogram. An ultrasonic technique used to image real-time 
cardiac tissue dimensions and blood flow velocities. 

















 In 1958, Streptomycin peucetius was isolated from soil by the Farmitalia 
Research Laboratory in southern Italy.  From Streptomycin peucetius, 
researchers were ultimately able to derive doxorubicin (DOX) (Di Marco et al., 
1964).  The DOX, trade name Adriamycin®, is a 14-hydroxy analog of 
daunorubicin.  The DOX is a member of the family of anthracyclines that has 
been established as a highly effective antineoplastic agent administered as a 
treatment for multiple cancers.  These antineoplastic agents are clinically 
prescribed to treat leukemia, non-Hodgkin lymphomas, breast cancer, 
Hodgkin's disease, and sarcomas (Young, Ozols, & Myers, 1981).  Although 
effective, DOX is oftentimes accompanied by a number of deleterious side 
effects on cardiac tissue, which may include arrhythmias, contractile 
abnormalities, dilated cardiomyopathy, and chronic heart failure (Narula et al., 
1996; Singal, Li, Kumar, Danelisen, & Iliskovic, 2000; Zhang, Shi, Li, & Wei, 
2009).  The mechanisms underlying the toxic effects of DOX still remain 
unclear; however, proposed actions include its interference with 
topoisomerase-II (Tewey, Chen, Nelson, & Liu, 1984), induction of apoptosis, 
and an increased generation of ROS (Minotti et al., 2004). 
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 The DOX can intercalate DNA leading to the inhibition of 
topoisomerase-II by stabilizing the DNA-topoisomerase-II complex.  Under 
normal conditions, topoisomerase-II is able to cleave the DNA double helix, 
thereby allowing DNA fragments to pass through the break before rejoining the 
two strands.  The formation of the ternary topoisomerase-II-DOX-DNA 
cleavage complex inhibits the function of topoisomerase-IIβ (Lyu et al., 2007).  
Topoisomerase-IIβ inhibition leads to DNA strand breakage and ultimately 
cellular apoptosis (Hilmer, Cogger, Muller, & Le Couteur, 2004; Zhang et al., 
2012).  The DOX can also induce cell death by activation of two apoptotic 
pathways, extrinsic and intrinsic. 
 The extrinsic and intrinsic pathways are the two main pathways that 
stimulate the caspases.  Activated when extracellular signals bind with 
transmembrane death receptors, such as the tumor necrosis factor, the 
extrinsic pathway can lead to apoptosis beginning with the activation of 
caspase-8 (Tait & Green, 2010).  The intrinsic pathway begins through the 
release of mitochondrial cytochrome c.  After release of cytochrome c into the 
cytosol, it forms an apoptosome complex by combining with apoptosis 
activating factor and procaspase-9.  This formation, in turn, leads to the 
activation of caspase-9.  Caspase-9 cleaves downstream caspases, thereby 
initiating apoptosis (Acehan et al., 2002; Salvesen & Dixit, 1997). 
Another proposed mechanism of DOX’s antineoplastic effects is 
oxidative stress.  Normal cells generate a modicum of ROS, which may play a 
positive role in the regulation of cell growth and intercellular signaling 
(Mantovani et al., 2003).  In order to combat the overproduction of ROS, cells 
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produce antioxidant enzymes that can control the concentration of free 
radicals to mitigate ROS-mediated damage.  These enzymes include 
superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase 
(GPX).  In a physiological milieu, the administration of DOX has been reported 
to generate a significant increase in the production of ROS (Balanehru & 
Nagarajan, 1992).  The condition of an imbalance between the antioxidant and 
pro-oxidant forces within and outside the cell is referred to as oxidative stress.  
This imbalance may lead to the damage of proteins, DNA, and lipids 
(Nordberg & Arnér, 2001). 
 A common form of a ROS-induced damage is lipid peroxidation (Hrelia 
et al., 2002; Tam et al., 2006).  The ROS attack and degrade polyunsaturated 
fatty acids leading to damage of the membrane structure which, in turn, 
compromises membrane integrity.  This cascade of events is referred to as 
lipid peroxidation.  Compromised membrane integrity can alter membrane 
receptor function, calcium homeostasis, and eventually induce apoptosis. 
Doxorubicin-Induced Cardiotoxicity 
 The DOX-induced cardiotoxicity is multifactorial and complex, involving 
both ultrastructural and functional changes.  Evidence indicates that the risk of 
cardiotoxicity rises with an increase in the cumulative dose of DOX (Shapiro et 
al., 1998; Von Hoff et al., 1979).  The DOX-induced cardiotoxicity can be 
broken down into three distinct categories: acute myocardial injury, chronic 
cardiotoxicity, and late-onset cardiac dysfunction.  Occurring immediately 
following a single dose of DOX, acute myocardial injury has been observed in 
the forms of hypotension, tachycardia, and arrhythmias (Herman, Mhatre, Lee, 
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Vick, & Waravdeker, 1971; Schimmel, Richel, van den Brink, & Guchelaar, 
2004).  The second type of DOX-induced cardiotoxicity, chronic cardiotoxicity, 
has been reported to be an established, clinically prevalent form on which 
great importance has been placed.  Chronic cardiotoxicity is characterized by 
tachycardia, left ventricular (LV) cavity dilation, exercise intolerance, and 
progressive cardiac injury (Ferrans, 1978).  Increased awareness has been 
made regarding the third category of DOX-induced cardiotoxicity, late-onset 
cardiac dysfunction.  Late-onset cardiac dysfunction becomes evident in the 
years to decades after treatment with DOX.  Key features of late-onset cardiac 
dysfunction include arrhythmias, LV systolic dysfunction, cardiomyocyte 
damage, and chronic heart failure (Schwartz et al., 1987; Steinherz et al., 
1991).  The dose-related significance of chronic and late-onset cardiotoxicity 
relating directly to increased mortality rates indicates that if a patient is given a 
cumulative dose in excess of 550 mg/m2 of body surface, morbidity rates 
dramatically increase (Singal & Iliskovic, 1998). 
 The heart is a high-energy organ reliant upon a constant supply of 
adenosine triphosphate (ATP) via mitochondrial oxidative phosphorylation.  
The targeted organelle by DOX-induced cardiotoxicity is the cardiomyocyte 
mitochondria.  Studies have demonstrated that DOX can accumulate in the 
mitochondria, and this may be due to the high affinity DOX has for the 
mitochondrial phospholipid cardiolipin (Goormaghtigh, Chatelain, Caspers, & 
Ruysschaert, 1980).  Cardiolipin is a phospholipid specific to the inner 
mitochondrial membrane and plays an integral part in electron transport chain 
assembly.  The attachment of DOX to cardiolipin creates a complex displacing 
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cardiolipin from key mitochondrial proteins.  This DOX-cardiolipin complex 
inhibits cytochrome c oxidase and mitochondrial enzymatic complex I and III, 
reducing ATP production and triggering apoptotic pathways (Goormaghtigh et 
al., 1980; Goormaghtigh, Huart, Praet, Brasseur, & Ruysschaert, 1990). 
 A central mechanism associated with DOX-induced cardiotoxicity is the 
overproduction of ROS and reactive nitrogen species (RNS).  As stated 
previously, cardiomyocytes are highly aerobic and require a constant supply of 
ATP by oxidation phosphorylation.  The DOX administration may lead to an 
overproduction of ROS and RNS, which leads to cardiotoxicity by the 
disruption of the cardiac sarcoplasmic reticulum and the mitochondrial 
respiratory chain.  The increased generation of ROS results mainly in the 
mitochondria where it undergoes redox cycling at complex I of the electron 
transport chain (Marcillat, Zhang, & Davies, 1989). 
 The quinone form of DOX can be converted to a semiquinone free 
radical through univalent reduction.  The semiquinone radical can then be re-
oxidized by a one-electron transfer to molecular oxygen, regenerating the 
parent quinone with superoxide anion (O2
•-) as a byproduct (Nohl, Gille, & 
Staniek, 1998).  Large amounts of O2
•- will be generated through redox cycling 
between the quinone and semiquinone forms of DOX.  The DOX-induced 
redox imbalance may lead to the excess generation of superoxide.   
 The superoxide radical can be converted to hydrogen peroxide (H2O2) 
by SOD.  From here, the anti-oxidative enzymes, CAT and GPX, reduce H2O2 
to water (H2O) (Harrison et al., 2005).  The overproduction of O2
•- can lead to 
increased production of H2O2.  The two radicals can react with one another, 
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forming a hydroxyl radical (OH), via the Harber-Weiss reaction.  This reaction 
can lead to lipid peroxidation (Radi, Beckman, Bush, & Freeman, 1991).  The 
H2O2 is able to traverse the mitochondrial membrane and generate an OH in 
the presence of iron, copper, cobalt, and chromium via the Fenton reaction 
(Henkler, Brinkmann, & Luch, 2010).   
 Ferritin is the main iron storage protein.  Release of iron from ferritin 
can occur in the presence of O2
•-.  It achieves this dissociation by 
disassembling the 4Fe-4S cluster.  In doing so, this phenomenon has been 
reported to increase the activity of iron regulating protein-1, leading to 
increased iron uptake.  The increases in free iron at the cellular level can react 
with H2O2, which is known as the Fenton reaction, forming an OH (Corna, 
Galy, Hentze, & Cairo, 2006). 
 The DOX can also induce the generation of RNS, such as nitric oxide 
(NO) and peroxynitrite (ONOO−).  The ONOO−, which is formed from NO and 
O2
•-, is a highly reactive radical, capable of damaging tissues and cells 
(Mccord, 1985).  The ONOO− also damages DNA by several mechanisms, 
such as single-strand breaks, leading to additional stress on the 
cardiovascular system (Szabó & Ohshima, 1997). 
Oxidative stress can also disrupt calcium homeostasis by impairing the 
ryanodine receptor (RYR) and sarcoendoplasmic reticulum ATPase 2 
(SERCA2).  The ROS promotes an open state of the RYR and a diminished 
effect of SERCA2.  This will cause a rise in intracellular calcium (Ca2+) and, in 
turn, may induce mitochondrial Ca2+ overload (Kim et al., 2006).  Mitochondrial 
Ca2+ overload triggers a mitochondrial permeability transition, which leads to 
13 
 
additional rise in calcium levels by altering the accessibility of mitochondria 
permeability transition pores (MPTP).  The Ca2+ overload may induce swelling 
of the mitochondria, rupturing of the outer mitochondrial membrane, resulting 
in the release of cytochrome c into the cytosol (Childs, Phaneuf, Dirks, Phillips, 
& Leeuwenburgh, 2002).  Release of cytochrome c will lead to the formation of 
an apoptosome complex which eventually leads to apoptosis (Sokolove & 
Shinaberry, 1988).  Oxidative stress can also alter the permeability of MPTP 
through the downregulation of anti-apoptotic proteins, such as B-cell 
lymphoma 2 and activation of pro-apoptotic proteins, Bcl-2-like protein 4, and 
Bcl-2 homologous antagonist/killer (Crompton, 1999).   
Doxorubicin-Induced Cardiac Dysfunction 
 Diminished LV function may be observed within the first six months 
after DOX treatment (Ali, Ewer, Gibbs, Swafford, & Graff, 1994).  Cardiac 
function may be assessed in vivo and ex vivo.  In vivo cardiac function can be 
analyzed by echocardiography, which assesses left ventricular end diastolic 
(LVDd) and end systolic diameter (LVDs), posterior wall thickness during 
diastole (PWd) and systole (PWs), septal wall thickness during diastole (SWd) 
and systole (SWs), and fractional shortening (FS).  Ex vivo function can be 
analyzed using an isolated working heart.  Measurements obtained from an 
isolated working-heart model include left ventricular developed pressure 
(LVDP), maximum rate of developed pressure (+dP/dt), minimum rate of 




 Studies suggest that acute DOX treatment causes cardiac dysfunction 
(Chicco et al., 2006; Wonders et al., 2008).  In a study by Wonders et al. 
(2008) it was found that DOX caused significant reductions in LVDP, ESP, and 
+dP/dt five days after a single bolus injection of 15 mg/kg.  The DOX treatment 
also led to significant increases in EDP and +dP/dt.  Cardiac dysfunction has 
also been noticeable with smaller acute doses of DOX (Hydock et al., 2008).  
Hydock et al. (2008) reported significant in vivo and ex vivo cardiac 
dysfunction 5 and 10 days following single bolus injections of DOX at 10 
mg/kg.  In vivo assessment indicated a significant depression of FS and 
significant decreases in SWs and SWd at both time points.  Ex vivo 
assessment showed that following treatment, LVDP and +dP/dt were 
significantly reduced at both time points.  Along with this, significant reductions 
in –dP/dt were also observed 10 days post injection.  
 Along with acute DOX treatment, studies have also examined altering 
the time course of treatment and cardiac function (Hayward & Hydock, 2007; 
Hydock et al., 2011).  A cornerstone study was carried out by Hayward and 
Hydock (2007) in which they examined in vivo cardiac function for acute and 
chronic dosing schedules.  Animals received 10 mg/kg of DOX by a bolus 
injection (group 1), 10 daily injections of 1 mg/kg/day (group 2), or five weekly 
injections of 2 mg/kg/wk (group 3).  Cardiac dysfunction was evident within the 
acute and chronic dosing groups.  Evidence of dysfunction appeared for all 
groups in the form of decreased FS.  Morphological changes resembling 
dilated cardiomyopathy were reported for all three groups.  Decreases in 
septal and posterior ventricular wall thicknesses were observed in the three 
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groups.  However, for groups 2 and 3 there was a delayed response in 
changes of cardiac geometry. 
Exercise Protection 
 It is widely acknowledged that chronic exercise training provides wide-
ranging benefits to a multitude of organs including the heart.  Studies have 
reported that different forms of exercise, such as treadmill running, wheel-
running, and swimming can attenuate DOX-induced cardiotoxicity.  
Mechanisms underlying the cardioprotection afforded by exercise may be 
dependent upon a number of factors including the dose of DOX, the modality 
of exercise, the temporal relationship between exercise and DOX treatment, 
subject comorbidities, gender, or even accompanying cancer therapies.  
Proposed mechanisms of cardioprotection have included reduced DOX 
accumulation within the cardiomyocyte (Jensen et al., 2013), attenuating 
unfavorable shifts towards β-myosin heavy chain (β-MHC) (Hydock et al., 
2008), decreased oxidative stress (Ascensão et al., 2005), and increased HSP 
expression (Ascensão, Ferreira, Oliveira, & Magalhães, 2006; Kavazis, 
Smuder, Min, Tümer, & Powers, 2010).  From available evidence, it appears 
that multiple mechanisms may be simultaneously involved with the protective 
effects of chronic aerobic exercise.   
Oxidative Stress 
 One of the main mechanisms for cardiotoxicity is the overproduction of 
ROS, which can lead to DNA damage and/or lipid peroxidation.  Various 
studies have presented results suggestive of exercise as a positive modulator 
of oxidative stress, which can be examined by the expression of key 
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antioxidant enzymes (Lennon et al., 2004; Somani, Frank, & Rybak, 1995) and 
one of the principle byproducts of lipid peroxidation, malondialdehyde (MDA) 
(Marques-Aleixo et al., 2014). 
 An early study by Quintanilha (1984) was one of the first to report an 
increase in antioxidant enzyme activity due to exercise training, and since then 
literature on the subject has expanded.  A study by Powers et al. (1993) was 
the first to examine the influence of intensity and duration of exercise training 
on the activity antioxidant enzymes.  Animals treadmill trained at one of the 
combinations of duration (30, 60, or 90 minutes) and intensity (low, moderate, 
or high) for 10 weeks.  Intensity was characterized as low (55% of maximal O2 
uptake), moderate (65% of maximal O2 uptake), and high (75% of maximal O2 
uptake).  Results indicated that high intensity exercise for all durations resulted 
in an increase SOD activity within the LV.  An increase in SOD activity was 
also observed in both low and moderate intensity when training was 60 
minutes or greater.  
 Along with these studies, an extensive amount of research has been 
conducted examining exercise-induced adaptations in antioxidant activity, 
which is believed to play a role in the attenuation or reduction of DOX-induced 
cardiotoxicity (Ascensão et al., 2006; Ascensão et al., 2005; Powers et al., 
1993).  Wonders et al. (2008) found that an acute bout of treadmill exercise 
significantly reduced lipid peroxidation in animals receiving a 15 mg/kg bolus 
injection of DOX.  Likewise, a more recent study by Ascensão et al. (2011), 
examined the effects of an acute bout of exercise on DOX-treated rats.  
Animals in the exercise group performed a 60-minute treadmill exercise bout 
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24 hours prior to receiving a DOX injection (20 mg/kg).  Results indicated that 
exercise provided a cardioprotective response from DOX treatment by 
increasing cardiac mitochondrial SOD activity and reducing caspase activity. 
 An early study by Kanter et al. (1985) was one of the first to report the 
effects of chronic aerobic exercise on DOX-induced oxidative stress.  The 
study examined the effects of a 21-week swim training program on antioxidant 
enzymes and DOX-associated cardiotoxicity.  The investigators reported that 
chronic exercise training led to physiological adaptations eliciting 
cardioprotective effects counteracting DOX, which may have been attributed to 
the upregulation of antioxidant enzymes.  This has been substantiated by 
studies examining different modes of exercise and the time course of 
treatment.  Kavazis et al. (2010) found that a short-term exercise training (10 
sessions) prior to a single bolus injection of DOX (20 mg/kg) increased 
manganese superoxide dismutase (MnSOD), copper zinc superoxide 
dismutase (CuSOD), CAT, and GPX while attenuating DOX-induced 4-
hydroxynonenal formation.  A study by Chicco et al. (2006) examined the 
effects of a long-term training program (12 weeks) prior to DOX treatment and 
reported a significant decrease in lipid peroxidation.  The role of oxidative 
stress on intracellular damage has been well-established.  The data suggest 
that exercise is an effective countermeasure to intracellular damage caused by 




Heat Shock Proteins 
 One mechanism by which exercise may protect the myocardium is 
through the induction of HSPs.  The HSPs serve as molecular chaperones 
during both protein assembly and membrane translocation.  An elevation of 
HSPs may play a protective role by preventing the denaturing of regulatory 
proteins, stabilizing newly denatured proteins, and protecting against 
apoptosis (Powers & Demirel, 2001). 
 Demirel et al. (1998) conducted a 10-week treadmill training program 
with rats and measured HSP72 expression.  Exercised animals ran 4 days per 
week and up to 90 minutes per day at 75% of maximal oxygen consumption 
(VO2max).  The investigators reported that exercise training was associated 
with a large (450%) increase in HSP72 in the LV.  A study conducted by Harris 
and Starnes (2001) had animals performing a three-, six-, or nine-week 
chronic exercise program.  After a week habituation of running on the treadmill 
at 6% incline for 10 minutes, the duration of the exercise was gradually 
increased to 60 minutes per day for five days a week by the end of week 
three.  The duration and intensity was maintained throughout the remaining 
weeks.  Animals in the exercise trained groups produced an 8.5-fold, 10.7-fold, 
and 12.3-fold increase in HSP70 in the LV, for three-, six-, and nine-week 
training groups, respectively.  Similarly, studies have examined cardiac HSP 
expression posttraining as a method to attenuate DOX-induced cardiac 
dysfunction.  A study by Chicco et al. (2006) reported an increase expression 
of HSP72 in an exercise group, which attenuated DOX-induced cardiac 
dysfunction.  Ample evidence has indicated that exercise can elicit altered and 
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increased expression of HSPs; however, evidence to support variations of 
intensity-related physiological adaptations has yet to be determined (Locke et 
al., 1995; Noble et al., 1999).  Despite evidence that increased HSP 
expression may provide a cardioprotective effect, studies have reported that 
this exercise-induced cardioprotection may be mechanistically independent to 
the observed increase in HSPs (Kavazis et al., 2010; Taylor, Harris, & 
Starnes, 1999). 
Myosin Heavy Chain Expression 
 The DOX treatment has been shown to induce an α-β shift in MHC 
isoforms, ultimately resulting in impaired cardiac function.  Aerobic exercise 
prior to and during DOX treatment has been shown to preserve α-MHC 
expression and attenuate DOX-induced cardiac dysfunction (Hydock et al., 
2012).  Hydock, Wonders, Schneider, and Hayward (2005) examined the 
effects of voluntary wheel running on MHC distribution during six weeks of 
DOX treatment.  It was concluded that exercise during DOX treatments leads 
to a significant increase in the expression of α-MHC when compared to the 
SED DOX group.  Furthermore, Hydock et al. (2008) examined if exercise 
preconditioning would provide a cardioprotective effect against a single bolus 
injection of DOX (10 mg/kg) and whether this was associated with altered 
MHC expression.  Animals performed a progressive treadmill training program 
for 10 weeks followed by DOX treatment and what was observed was a 
preservation of MHC isoform distribution that could be linked to 
cardioprotection.  DOX-induced cardiac dysfunction may be influenced by a 
noticeable shift in MHC expression from α to β isoforms.  Evidence suggests 
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that preservation of α-MHC expression may play a mechanistic role in 
exercise-induced cardioprotection.  Although the percentage of cardiac α-MHC 
isoform differs greatly between humans (< 3%) and rats (> 90%), its 
expression plays an important role in human cardiac function (Miyata, Minobe, 
Bristow, & Leinwand, 2000).  A study by Lowes et al. (1997) reported a 
downregulation of α-MHC with a corresponding upregulation of β-MHC in 
failing ventricular myocardium.  The α to β shift is linked to significant 
decreases to cardiac contractility (Tardiff et al., 2000). 
Doxorubicin Accumulation 
 The DOX treatment can lead to its accumulation in tissues including 
skeletal and cardiac muscle which may explain functional decrements 
(Hayward et al., 2013).  Recent studies from our laboratory have reported that 
exercise, both voluntary wheel running and treadmill training, resulted in 
decreased DOX accumulation (Gibson, Quinn, Pfannenstiel, Bashore, et al., 
2013; Jensen et al., 2013).  From these studies, it appears as though 
preservation of cardiac function may be influenced by a decrease in DOX 
accumulation (Jensen et al., 2013).  
 The accumulation of DOX within cardiomyoctyes may be a result of 
multidrug resistance protein (MRP) regulation.  MRPs are a part of the 
superfamily of ATP binding cassette (ABC) transporters that function as drug 
efflux pumps.  Multiple types of MRPs have been reported to be expressed in 
cardiac tissue, including MRP-1, MRP-2, and MRP-7 (Gibson, Quinn, 
Pfannenstiel, Hydock, & Hayward, 2013).  Evidence has indicated that 
exercise can increase expression of myocardial MRP-1, MRP-2, and MRP-7, 
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which can lead to the preservation of cardiac function as a result of decreases 
in DOX accumulation (Gibson, Quinn, Pfannenstiel, Bashore, et al., 2013; 
Krause et al., 2007). 
Resistance Training 
 The benefits of acute and chronic aerobic exercise on cardiac 
dysfunction have received a great deal of attention.  Since myocardial tissue 
relies heavily on oxidative metabolism, much of the research has focused on 
aspects of oxidative metabolism; there is a limited amount of research 
investigating the cardioprotective effects of resistance exercise training.  
Though limited, some studies have indicated beneficial effects to both 
physiological and pathological processes.   
 The beneficial effects of RT training may be influenced by the 
adaptations that occur to the cardiovascular system.  Similar to aerobic 
training, physiological cardiac hypertrophy can occur with RT.  Characteristics 
of the cardiac hypertrophy, however, differ between the two due to the type of 
circulatory overload that occurs with RT (Pluim, Zwinderman, van der Laarse, 
& van der Wall, 2000).  Possible adaptations that may occur include increased 
interventricular septum and wall thickness, which has led to this type of 
hypertrophy being termed concentric cardiac hypertrophy.  Concentric cardiac 
hypertrophy has been observed in pathological conditions such as 
hypertension, which can be linked to systolic and diastolic dysfunction 
(Barauna, Rosa, Irigoyen, & de Oliveira, 2007).  However, it has been 
indicated that the cardiac hypertrophy observed from RT will not lead to 
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abnormalities in function but may enhance systolic function (Colan, Sanders, & 
Borow, 1987; Levinger, Bronks, Cody, Linton, & Davie, 2005). 
 Not only can RT influence hypertrophy, it can also provide 
cardioprotection against intracellular damage.  In order to induce adaptions 
that will, in turn, attenuate oxidative stress, an acute bout of exercise must 
actually elicit oxidative stress.  Studies have reported that an acute bout of a 
resistance exercise can cause an increase in ROS as well as can lead to an 
attenuation of oxidative damage (Goldfarb, Bloomer, & McKenzie, 2005; 
McBride, Kraemer, Triplett-McBride, & Sebastianelli, 1998; Vincent, Vincent, 
Braith, Lennon, & Lowenthal, 2002).  The above studies do indicate that an 
acute bout of resistance exercise can induce oxidative stress as well as serve 
as a stimuli, which will attenuate it; however, studies that look specifically at 
myocardial oxidative stress are extremely limited.  Chicco et al. (2006) 
examined the effects of a six-week RT program on cardiac oxidative stress 
caused by alcohol consumption.  Rats were assigned to one of four groups: 
SED, SED plus alcohol treatment, RT, or RT plus alcohol treatment.  The 
exercise groups trained by standing on their hind limbs while wearing a 
weighted vest.  Training activity was repeated 30 times per session three days 
a week.  The load lifted was incrementally increased by 20% of the animal’s 
body weight each week.  Results of the study indicated that this type of RT 
attenuated ethanol-induced cardiac lipid peroxidation.  The studies above 
indicate that resistance exercise can induce cellular damage, which in turn can 
lead to an adaptation whereby the cell is protected against oxidative stress. 
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 The RT-induced cardioprotection, in the form of improved cardiac 
function, has also been observed with other models.  A study by Soufi, Saber, 
Ghiassie, and Alipour (2011) showed the cardioprotective effects of a 12-week 
RT program against ischemia-reperfusion-induced injury in rats.  Training was 
performed on a squat-training apparatus in which rats would stand on their 
hind legs.  Through an electrical stimulation of the rat’s tail, hind limbs would 
contract, raising a weighted piston that was located above the animals head.  
Animals performed four sets of 12 repetitions per day, with a 90-second rest 
period between each set, five times per week for 12 weeks.  The investigators 
noted that the observed significant (p < .05) increases in LVDP indicated that 
this type of RT model can provide cardioprotection against myocardial injuries.  
This RT-induced improvement in cardiac function has also been observed in 
patients with mild and chronic congestive heart failure (Levinger et al., 2005; 
Palevo, Keteyian, Kang, & Caputo, 2009).  These studies suggest that 
resistance exercise training may provide protection against treatments and 
conditions that cause myocardial injury. 
Summary 
 Although DOX is limited by a dose-dependent cardiotoxicty, it still 
remains one of the most effective antieoplastic agents used to treat a variety 
of cancers.  Acute and chronic DOX treatments may elicit varying degrees of 
cardiac dysfunction including arrhythmias, LV cavity dilation, and chronic heart 
failure.  Though we continue to learn more about the mechanisms behind the 
development of cardiotoxicity, it has been proposed that uncontrolled 
generation of ROS plays a key role.  Exercise has been shown to mitigate 
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DOX-induced cardiotoxicity and preserve cardiac function.  This exercise-
induced attenuation is thought to be linked to a variety of positive physiological 
adaptations including increased HSP capacity, decreased caspase activity, 
preservation of the cardiac MHC isoform distribution, and increased 
antioxidant activity.  Multiple studies have implemented treadmill or voluntary 
wheel running as the modality of exercise intervention, while few researchers 
have examined the effects of RT on DOX-associated toxicity.  Therefore, the 
purpose of this study was to determine the effects of chronic resistance 
exercise preconditioning on DOX-induced cardiac dysfunction and DOX-
















 The exercise modality implemented in this study mimicked resistance 
exercise training and consisted of a raised-caged model, which forces animals 
to assume an erect bipedal stance while feeding and drinking.  Following 12 
weeks of training, a bolus 12.5 mg/kg doxorubicin (DOX) injection was 
administered 24 hours after trained animals had been placed into non-
elevated cages.  Control animals received a bolus intraperitoneal injection of 
0.9% SAL.  Rats were sacrificed five days after DOX treatment, and cardiac 
function was analyzed both in vivo and ex vivo.  Following ex vivo cardiac 
function assessment, the LV was isolated and flash frozen in liquid nitrogen for 
biochemical analysis. 
Subjects 
 Ten-week-old male Sprague Dawley rats (N = 48) were randomly 
assigned to sedentary (SED) (n = 24) or RT (n = 24) groups in a temperature-
controlled facility with a 12:12-hour light-dark cycle.  Rats were provided 
standard rat chow and water ad libitum.  All protocols used for the study were 
approved by the University of Northern Colorado Institutional Animal Care and 
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Use Committee and was in compliance with the Animal Welfare Act guidelines 
(see Appendix). 
Exercise Training 
 Animals that were randomly assigned to the RT group were placed in 
cages that allow for a progressive elevation of food and water, encouraging 
the animals to rise to a bipedal stance each time they eat and drink.  Cage 
height was raised to specified heights using specially designed plastic spacers 
that sat between the standard cage and the standard cage lid.  Placement of 
the spacers between the cage and the lid raises the food and water to the 
desired height.  This RT model has been shown to increase hind limb muscle 
mass and increased tibial cortical bone (Yao, Jee, Chen, Li, & Frost, 2001).  
On day one of the training protocol, cage height was raised from the standard 
20.32 cm to a height of 28 cm.  Cage height remained at 28 cm for one week.  
Following the first week, the height was raised by 2.5 cm.  From there, every 
third day cages were raised 2.5 cm until they reach the final height of 35.5 cm.  
This height was maintained for an additional 10 weeks for a total of 12 weeks 
of training.  Food and body weight were recorded daily, and adequate water 
consumption was confirmed for the first three weeks of training to ensure 
animals were able to reach both food and water.  Following the first three 
weeks of training, animals had their food measured and water monitored three 
days per week, and body weight was measured weekly.   
 At the completion of the 12-week training period, all plastic spacers 
were removed so that that all food and water returned to the standard cage 
height.  This was done to ensure that there were no effects of acute exercise 
27 
 
on the observed dependent variables.  All animals remained in these standard 
cages for 24 hours prior to DOX treatment.  Following the 24-hour period, 
each animal was randomly assigned to one of four groups: SED+SAL (n = 9), 
SED+DOX (n = 15), RT+SAL (n = 9), and RT+DOX (n = 15).  The SAL groups 
received a bolus intraperitoneal 0.9% SAL injection, and the DOX group 
received a bolus intraperitoneal 12.5 mg/kg DOX injection. 
 Various exercise modalities have been used to mimic RT.  These 
include tower climbing (Notomi et al., 2001), an erected bipedal stance 
exercise with a weighted vest (Westerlind et al., 1998), and an erected bipedal 
stance whole-body exercise (Yao et al., 2000).  Consistent findings have 
observed that an exercise modality that mimics RT can cause adaptation to 
bone, skeletal muscle, and cardiac muscle (Barauna et al., 2007; Duncan, 
Williams, & Lynch, 1998; Notomi et al., 2001).  There is no standard or set 
protocol for laboratory animal weight-bearing exercise modalities.  The range 
of total repetitions and total resistance varies greatly between studies.   
 The RT model has been used by others (Mo et al., 2002; Rosa, Firth, 
Blair, Vickers, & Morel, 2011; Yao et al., 2000) and pilot studies in our 
laboratory.  Recently in our laboratory, the RT model has been associated with 
positive functional adaptations in skeletal muscle, which have also been 
observed following resistance protocols discussed previously.  These data, 
along with the pilot study, suggest that the exercise modality may be an 
effective model for exercise-induce cardiac adaptations. 
28 
 
Assessment of Cardiac Function  
In Vivo Cardiac Function 
 In vivo cardiac function was analyzed five days after DOX treatment via 
echocardiography.  Animals were sedated with ketamine (40 mg/kg, 
intraperitoneal), and the anterior and left lateral thoracic regions were shaved.  
Transthoracic echocardiography was conducted on the sedated rats using a 
General Electric Vivid 7 ultrasound with a 10-MHz introperative transducer 
(Tustin, California).  Measurements of septal wall thickness during systole and 
diastole, posterior wall thickness during systole and diastole, LV end systolic 
and diastolic diameter, and FS were acquired by M-mode tracings of the LV 
obtained in a short axis view.  From an apical view using a pulsed-wave 
Doppler, aortic and mitral blood flow echocardiographic images were obtained 
providing measurements of maximal flow velocity for both aortic and mitral 
valves.  All echocardiographic measurements were averaged from three 
consecutive cardiac cycles.  All M-mode and Doppler measurements were 
made in accordance with guidelines established by the American Society of 
Echocardiography. 
Ex Vivo Cardiac Function 
 Ex vivo cardiac function was analyzed following echocardiography via 
an isolated working-heart model (ADInstruments, Colorado Springs, 
Colorado).  Each animal was anesthetized using an intraperitoneal injection of 
heparinized (500 U) sodium pentobarbital (50 mg/kg).  Following an absent tail 
pinch reflex, the heart was excised and placed into ice cold Krebs-Henseleit 
buffer (in mM: 120 NaCl, 5.9 KCl, 2.5 CaCl2, 1.2 MgCl, 25 NaHCO3, 17 
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glucose, and 0.5 ethylenediaminetetraacetic acid [EDTA]) aerated with 95% 
O2 – 5% CO2.  Hearts were quickly cannulated by the ascending aorta and 
subjected to retrograde perfusion until all blood was cleared from the coronary 
vasculature.  The pulmonary vein was then cannulated, and blood flow was 
redirected from the aorta to the left atrium to initiate the working-heart model.  
Once stabilized, a microtip catheter pressure transducer (Millar Inc., Houston, 
Texas) was placed into the LV via the apex for determination of LV developed 
pressure (LVDP), LV maximal rate of ventricular pressure development 
(+dP/dt), and LV rate of pressure decline (-dP/dt).  Preload was set at 10 
cmH2O and was maintained for all subsequent functional measurements.  
Afterload was progressively increased every three to five minutes during data 
collection from 85 cmH2O, to 100 cmH2O, and to 115 cmH2O.  After data were 
collected at the three different afterloads, afterload was adjusted to 100 
cmH2O, and hearts were paced at 240 beats per minute using electrodes 
attached to the cannula.  The LV functional data were collected and analyzed 
using a PowerLab data acquisition system (ADInstruments).  Once data were 
collected, hearts were trimmed of connective tissue and fat and weighed.  The 
LVs were then isolated, flash frozen in liquid N2, and stored at –80°C until 
subsequent biochemical analyses.  
Biochemical Analysis 
Lipid Peroxidation 
A commercially available assay kit (Bioxytech MDA-586, Oxis 
Research, Foster City, California) was used to measure malondialdehyde + 
4˗hydroxyalkenal (MDA + 4-HAE) as an indicator of cellular lipid peroxidation.  
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Tissues were homogenized in a radioimmunoprecipitation buffer for the assay.  
A 200 µL aliquot of each sample was added to a microcentrifuge tube followed 
by 650 µL of N-methyl-2-phenylindole in acetonitrile and briefly vortexed.  
Next, 150 µL of methanesulfonic acid was added, vortexed, and incubated at 
45°C for 60 minutes.  Samples were then centrifuged at 10,000 g for 10 
minutes.  The resulting supernatant was transferred to a cuvette and 
absorbency measured using a spectrophotometer at 586 nm.  The MDA + 4-
HAE was estimated from a standard curve.  All samples were assayed in 
duplicate, and any samples varying more than 5% were reassessed. 
Myosin Heavy Chain Analysis 
 Sample preparation was adapted from the method of Thomason, 
Baldwin, and Herrick (1986).  Approximately 100 mg of LV tissue was minced 
in a 2 mL glass tissue homogenizer with surgical scissors.  A 1:10 
weight/volume ratio of homogenization buffer (250 mM sucrose, 100 mM KCl, 
5 mM EDTA, and 20 mM Tris-Base, 4°C, pH 6.8) was added to the 
homogenizer.  The sample was homogenized approximately five minutes 
using a ScilogexD160 homogenizer (Rocky Hill, Connecticut).  Homogenates 
were centrifuged at 1,000 g for 10 minutes at 4°C and pellets collected and 
resuspended, with the same volume as the homogenization buffer, in a 
washing buffer (175 mM KCl, 0.5% Triton X-100, 2 mM EDTA, and 20 mM 
Tris-Base, 4°C, pH 6.8).  Samples were centrifuged again at 1,000 g for 10 
minutes at 4°C.  The pellets were collected, resuspended with the same 
volume as the previous washing buffer, and centrifuged at 1,000 g for 10 
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minutes at 4°C.  The pellets were resuspended in the final resuspension buffer 
(150 mM KCl, and 20 mM Tris-Base, pH 7.0) at 1/12 of the previous volume.   
 Total protein concentration was determined using the Bradford protein 
assay method (Bradford, 1976).  Samples were then diluted to 2 mg/mL with 
the final resuspension buffer.  Twenty-five µL of each sample was further 
diluted to 0.125 mg/mL with 2x Laemmli sample buffer (20% glycerol, 16% 1M 
Tris [pH 6.8], 4% sodium dodecylsulfate [SDS], 1% β-mercaptoethanol, and 
0.2% bromophenol blue).  To denature the proteins, samples were boiled for 
two minutes and then placed on ice for another 10 minutes.  Following the 10 
minutes on ice, samples were loaded onto polyacrylamide gels. 
 A SDS polyacrylamide gel electrophoresis was used to determine MHC 
isoform expression.  The MHC gel composition used the modified method of 
Reiser and Kline (1998) from the original method of Talmadge and Roy 
(1993).  A 0.75 mm Snap-A-Gel cassette (Jule, Inc., Milford, Connecticut) was 
used to cast polyacrylamide gels.  The gel polymerization of separating gels 
(5% of 100% glycerol, 8% acrylamide-N,N'-methylene, 4% acrylamide-bis 
[50:1], 0.2 M Tris-Base [pH 8.8], 0.1 M glycine, and 0.4% of 10% SDS) was 
initiated by adding 0.05% N,N,N',N'- tetramethylethylenediamine and 0.1% 
ammonium persulfate (10%).  After initiating the gel polymerization, the 
separating gel solution was pipetted into cassettes to approximately 1 cm 
below the height of the bottom of comb.  N-butonol was then pipetted to the 
top of the gel in order to flatten the separating gel during polymerization.  
Cassettes were then placed in the refrigerator for at least 60 minutes to allow 
the gel to polymerize.   
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 Following polymerization of the separating gel, n-butanol was removed 
and cassettes rinsed five times with milli-pure water.  The polymerization of 
the stacking gel (5% of 100% glycerol, 4% acrylamide-bis [50:1], 70 mM Tris-
Base [pH 6.7], 4 mM EDTA and 0.4% of 10% SDS) was initiated by adding 
0.05% tetramethylethylenediamine and 0.1% ammonium persulfate (10%).  
The stacking gel solution was pipetted to the top of the separating gel and a 
10-lane comb was inserted (Jule, Inc.) into the stacking gel.  Cassettes were 
then placed in the refrigerator for at least 60 minutes to allow the stacking gel 
to polymerize.  
 Following polymerization of the stacking gel, combs were removed.  
Cassettes were placed into Novex Sure Lock cells (Invitrogen Corporation, 
Carlsbad, California).  Cassettes were locked and then the middle chamber 
was filled with upper running buffer (0.1 M Tris, 150 mM glycine, and 0.1% 
SDS).  Next, 7.5 µL of BenchMark™ protein standard (Invitrogen Corporation) 
was loaded in the first lane.  Following the protein standard, 7 µL of the 
samples was loaded in the remaining lanes.  Lower running buffer (50 mM 
Tris, 75 mM glycine, and 0.05% SDS) was poured into the outside chamber of 
the electrophoresis unit.   
 Electrophoresis was conducted at 100 V, 25 mA for approximately three 
hours or until the tracking dye was near the bottom of the gel.  The gels were 
then stained with Simply Blue safe stain for 60 minutes.  Gels were then 
placed in distilled water overnight.  The following day, gels were removed and 
placed between two transparency sheets and scanned.  The density of MHC 
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protein bands was analyzed using Image J densitometry software (National 
Institutes of Health, Bethesda, Maryland). 
Statistical Analysis 
 Data were analyzed and presented using GraphPad Prism statistical 
software.  All data are expressed as mean ± standard deviation (M ± SD).  A 
two-way analysis of variance (ANOVA) was used to determine significant 
difference due to the main effects (DOX and RT) and interaction.  Upon 
observation of a significant difference, a Tukey post-hoc pair-wise comparison 
was conducted to evaluate any pair-wise comparisons.  For all statistical 















 The purpose of this study was threefold: (a) to examine the effects of 
chronic RT prior to the administration of doxorubicin (DOX) on in vivo and ex 
vivo cardiac function in male Sprague Dawley rats, (b) to determine if any 
cardioprotective effects are a result of a reduction in lipid peroxidation, and (c) 
to determine if any cardioprotective effects are a result of a preservation of the 
cardiac MHC isoform distribution.  
General Observations 
General observations are presented in Table 4.1.  Six animals died 
during the course of this experiment, making the total mortality rate 20% for 
DOX treated-animals.  Resistance training cut mortality in half, with SED+DOX 
having a mortality rate of 27% (4/15); whereas, the mortality rate for RT+DOX 
was 13% (2/15).  Animals in both SAL groups continued to gain body weight in 
the five days following injection; however, these gains were not significant.  A 
2-way ANOVA on final body weight revealed a drug effect, F(1, 38) = 29.2, p < 
0.0001, with the DOX-treated animals’ body weight significantly lower than the 
SAL-treated animals.  Five days following injection, body weight decreased 
14% for both DOX groups, with no statistically significant difference between 
DOX groups.  A 2˗way ANOVA on absolute heart mass revealed both a drug 
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effect, F(1, 38) = 6.757, p = 0.0132, and activity effect, F(1, 38) = 11.33, p = 
0.0018.  Absolute heart mass was significantly higher in the RT+SAL group 
compared to SED+DOX.  Relative heart mass also showed a drug effect, 
F(1, 38) = 5.448, p = 0.025, and activity effect, F(1, 38) = 18.87, p = 0.0001.  
Both RT groups had greater heart mass when compared to SED+SAL.  

























M ± SD 
 
 
Relative heart mass 
(%) 






    9 
 
441 ± 37 
 
446 ± 36 
 
1.5 ± 0.18 
 




    9 
 
439 ± 57 
 
442 ± 54 
 
1.7 ± 0.17† 
 





  11 
 
447 ± 31 
 
386 ± 26 
 
1.4 ± 0.14 
 





  13 
 
446 ± 23 
 
384 ± 22 
 
1.6 ± 0.13 
 
0.40 ± 0.04* † 
 
Note. Data are represented as M ± SD.  SED = sedentary; RT = resistance trained; 
SAL = saline placebo; DOX = doxorubicin.  p < 0.05.  
*p < 0.05 versus SED+SAL. 








 Cardiac geometry (see Table 4.2) and blood flow velocities (see Table 
4.3) were measured by echocardiogram.  No statistically significant differences 
were seen between the groups for SWd, PWs, PWd, LVDs, and FS.  Five 
days post injection, a 2-way ANOVA on SWs revealed a drug effect, F(1, 38) = 
13.39, p = 0.0008.  A post hoc analysis determined that SED+DOX SWs was 
significantly thinner (p < 0.05) compared to both SAL groups.  A drug effect, 
F(1, 38) = 14.45, p = 0.0005, was also observed on LVDd.  A post hoc 
analysis determined that both SAL groups LVDd was significantly greater (p < 
0.05) than RT+DOX.  Echocardiography Doppler images were used to analyze 
maximum blood flow through the aortic valve (A-Vmax) and mitral valve (M-
Vmax).  A 2-way ANOVA on the A-Vmax revealed a drug effect, F(1, 38) = 
79.25, p < 0.0001, activity effect, F(1, 38) = 15.03, p = 0.0004, and an 
interaction, F(1, 38) = 13.42, p = 0.0008.  The M-Vmax also had a drug effect, 
F(1, 37) = 82.44, p < 0.0001, activity effect, F(1, 37) = 7.002, p = 0.0119, and 
interaction, F(1, 37) = 13.32, p = 0.008.  Significant decreases in A-Vmax and 
M-Vmax occurred with both DOX groups when compared to both SAL groups.  
However, RT+DOX A-Vmax and M-Vmax was significantly faster (p < 0.05) 






















































































































































Note. Data are represented as M ± SD.  SED = sedentary; RT = resistance 
trained; SAL = saline placebo; DOX = doxorubicin; SWs = septal wall 
thickness during systole; SWd = septal wall thickness during diastole; PWs = 
posterior wall thickness during systole; PWd = posterior wall thickness during 
diastole; LVDs = left ventricular end systolic diameter; LVDd = left ventricular 
end diastolic diameter; FS = fractional shortening. 
*p < 0.05 versus SED+DOX. 


















































68 ± 10* 
 
13 
         
A-Vmax 74 ± 15*† 9 31 ± 10 11 75 ± 10*† 9 57 ± 10* 13 
 
 
Note. Data are represented as M ± SD.  SED = sedentary; RT = resistance 
trained; SAL = saline placebo; DOX = doxorubicin; M-Vmax = maximum blood 
flow through mitral valve; A-Vmax = maximum blood flow through aortic valve. 
*p < 0.05 versus SED+DOX. 




Isolated Perfused Working Heart 
 Following echocardiographic measurements, the cardiac variables 
ESP, EDP, LVDP, +dP/dt, -dP/dt, and heart rate were analyzed using an 
isolated working-heart apparatus.  Afterload was set at three different heights 
(85, 100, and 115 cmH2O) during the analysis.  No statistically significant 
differences in heart rate and EDP were observed between the four groups at 
any of the afterloads.  Cardiac function at the three different afterloads is 
displayed in Figure 4.1.  At an afterload of 85 cmH2O, an interaction was 
observed for ESP, LVDP, and +dP/dt.  A post hoc analysis revealed that both 
SAL groups and RT+DOX had significantly higher (p < 0.05) ESP, LVDP, and 
+dP/dt when compared to SED+DOX.  Although RT+DOX was significantly 
higher than SED+DOX in ESP (34%) and LVDP (37%), RT+DOX ESP and 
LVDP were significantly lower than both SAL groups. 
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At an afterload of 100 cmH2O, an interaction was observed for ESP, 
LVDP, and +dP/dt.  A post hoc analysis revealed that both SAL groups and 
RT+DOX had significantly higher ESP, LVDP, and +dP/dt when compared to 
SED+DOX.  The SED+DOX –dP/dt was also significantly less when compared 
to SED+SAL.  Similar to an afterload of 85 cmH2O, RT+DOX was significantly 
higher than SED+DOX in ESP (44%) and LVDP (46%); however, the group 
was significantly lower when compared to both SAL groups.  The RT+DOX 
+dP/dt was also significantly lower when compared to SED+SAL.  
At an afterload of 115 cmH2O, an interaction was observed for ESP, 
LVDP, and +dP/dt.  A post hoc analysis revealed that both SAL groups and 
RT+DOX had significantly higher ESP, LVDP, +dP/dt, and –dP/dt when 
compared to SED+DOX.  Although RT+DOX was significantly higher than 
SED+DOX in ESP (44%), LVDP (46%), and +dP/dt (15%), RT+DOX ESP, 






Figure 4.1. Unpaced ex vivo cardiac function.  (A) end systolic pressure, (B) end 
diastolic pressure (C) left ventricular developed pressure, (D) maximal rate of 
developed pressure, and (E) maximal rate of pressure decline.  Values are M ± SD.  
SED = sedentary; RT = resistance trained; SAL = saline placebo; DOX = doxorubicin. 
Ψ significant differences between SED+SAL and SED+DOX 
# significant differences between RT+SAL and SED+DOX 
† significant differences between RT+DOX and SED+DOX 
* significant differences between SED+SAL and RT+DOX 
Ω significant difference between RT+SAL and RT+DOX 
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Paced cardiac function at an afterload of 100 cmH2O is displayed in 
Figure 4.2.  Following the collection of unpaced data, the afterload was placed 
at 100 cmH2O and LV pressure was measured at a standardized pace of 240 
beats/min.  An interaction was observed for ESP, LVDP, +dP/dt, and -dP/dt.  
Both SAL groups and RT+DOX had significantly higher ESP, LVDP, +dP/dt, 
and –dP/dt when compared to SED+DOX.  No significant differences were 
seen between RT+DOX and SAL groups for all variables. 
 
 
Figure 4.2. Paced ex vivo cardiac function.  (A) end systolic pressure, (B) left 
ventricular developed pressure, (C) maximal rate of developed pressure, and 
(D) maximal rate of pressure decline.  Values are M ± SD. 




 As afterload increases, the normal physiological response is an 
increase in LV pressure.  Although not significant, increases (~ 5%) were 
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observed for both SAL groups in ESP, LVDP, and +dP/dt as the afterload 
increased from 85 cmH2O to 115 cmH2O.  Both DOX groups showed little 
(< 2%) to no change in ESP, LVDP, +dP/dt, and –dP/dt as the afterload was 
increased from 85 cmH2O to 115 cmH2O. 
Biochemical Analysis 
 All data from biochemical analyses are presented in Table 4.4 and 
Figures 4.3 and 4.4.  To provide an index of oxidative stress in the 
myocardium, MDA + 4-HAE levels were analyzed.  A 2-way ANOVA on MDA 
+ 4-HAE levels revealed a drug effect, F(1, 38) = 20.01, p < 0.0001.  A post 
hoc analysis was performed to examine group differences.  No significant 
difference was seen within both DOX-treated and SAL-treated animals, 

















 M ± SD M ± SD M ± SD M ± SD 
 
MDA + 4-HAE (pmol/mg) 
 
679 ± 94*† 
 
896 ± 194 
 
673 ± 105*† 
 
829 ± 109 
 
β-MHC (%) 9 ± 3*† 36 ± 12 17 ± 8* 25 ± 9* 
 
Note. Data are represented as M ± SD.  SED = sedentary; RT = resistance trained; SAL = 
saline placebo; DOX = doxorubicin; MDA = malondialdehyde; HAE = hydroxyalkenal; MHC = 
myosin heavy chain. 
*p < 0.05 versus SED+DOX. 





The MHC isoform distribution was examined to determine if an isoform 
shift played a protective role in DOX-induced cardiac dysfunction.  A 2-way 
ANOVA on percentage of β-MHC revealed a drug effect, F(1, 38) = 39.83, p < 
0.001.  Additionally, an interaction effect was observed, F(1, 38) = 11.74, p = 
0.0015.  A post hoc analysis was performed to examine group differences.  
SED+DOX observed a significant increase in the percentage of β-MHC 
expression when compared to both SAL groups.  The RT+DOX relative β-
MHC expression was significantly higher than SED+SAL but not RT+SAL.  
The RT+DOX percentage of β-MHC was significantly lower than SED+DOX, 



















Figure 4.3.  Myocardial lipid peroxidation in left ventricular homogenates.  SED 
= sedentary; RT = resistance trained; SAL = saline placebo; DOX = 
doxorubicin.  Values are M ± SD.  MDA = malondialdehyde; HAE = 
hydroxyalkenal. 
*significantly different than SED+SAL  






















Figure 4.4. β-myosin heavy chain expression in left ventricular homogenates.  
Panel A is a representative scan, via ImageJ, from each group.  Panel B is the 
β-myosin heavy chain expression in the left ventricle.  SED = sedentary; RT = 
resistance trained; SAL = saline placebo; DOX = doxorubicin; MHC = myosin 
heavy chain.  Values are M ± SD.  
*significantly different than SED+DOX. 



















Cancer is one of the leading causes of morbidity and mortality 
throughout the world.  In 2015 it is estimated that there will be more than 1.6 
million new cases of cancer diagnosed in the United States (Siegel, Miller, & 
Jemal, 2015).  In addition, it is estimated that more than 580,000 people will 
succumb to the disease in 2015, thus statistically making cancer the second 
most common cause of death in the United States.  Increased survival rates 
for cancer patients are due, in part, to progressive methods of prevention, 
detection, and treatment options available to patients.  Increased survival rates 
have led to a greater emphasis on improving overall quality of life in cancer 
survivors, with a particular focus on reducing or attenuating treatment-related 
side effects. 
 A Food and Drug Administration approved chemotherapeutic agent 
successful in the treatment of a variety of cancers is doxorubicin (DOX), 
clinically known as Adriamycin®.  Clinicians began prescribing DOX to cancer 
patients as a chemotherapy treatment in 1974.  Since then, it has been used 
to treat a variety of malignancies, both solid and hematological (Weiss, 1992).  
While substantially effective at treating cancer, the implementation of DOX into 
46 
 
routine cancer treatment regimens has been limited due to its known 
cardiotoxicity.  This well-characterized, dose-dependent cardiotoxicity can be 
manifested as cardiac dysrhythmias, contractile dysfunction, or even 
congestive heart failure (Steinherz, Steinherz, Tan, Heller, & Murphy, 1991).  
Studies have indicated that DOX treatment will significantly reduce systolic 
and diastolic function in an isolated perfused heart.  Mechanistic actions of 
DOX that have been reported to induce cardiotoxicity include interference with 
deoxyribonucleic acid (DNA) strand separation during replication (Bachur et 
al., 1992), induction of apoptosis (Wonders, Hydock, Greufe, Schneider, & 
Hayward, 2009), and excess generation of reactive oxygen species (ROS) 
(Minotti, Menna, Salvatorelli, Cairo, & Gianni, 2004). 
Other studies have examined one of the central mechanisms of DOX-
induced cardiotoxicity, oxidative stress, by measuring lipid peroxidation.  
These studies have determined that DOX treatment leads to significant 
increases in lipid peroxidation, which initiates a cascade of events causing 
diminished cardiac function.  The increase in lipid peroxidation has been linked 
to a change in myosin heavy chain (MHC) isoform distribution (Aragno et al., 
2006).  The MHC isoform distribution plays an essential role in cardiac 
contractile properties.  An alteration in MHC isoform distribution is reported to 
cause diminished contractile velocity (Ramamurthy, Hook, Jones, & Larsson, 
2001). 
 Aside from examining ways to prevent, diagnose, and treat cancer, 
researchers have diligently investigated interventions aimed at the reduction or 
attenuation of burdensome side effects commonly accompanying cancer 
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treatment.  Purported to counteract many of the transient and chronic effects 
associated with cancer treatments, the role of regular exercise in the 
prevention and treatment of cancer has been the focus of much clinical 
research over the past 15 years.  
 Studies have suggested that exercise preconditioning may reduce 
DOX-induced cardiotoxcity following treatment (Hydock, Lien, Jensen, 
Schneider, & Hayward, 2011; Hydock, Lien, Schneider, & Hayward, 2008; 
Jensen, Lien, Hydock, Schneider, & Hayward, 2013).  However, not fully 
understood are the mechanisms involved with the induction of exercise-
mediated cardioprotection.  Exercise-induced cardioprotection against DOX 
toxicity may be explained by upregulation of heat shock proteins (HSP) 
(Chicco, Schneider, & Hayward, 2005), down-egulation of pro-apoptotic 
pathways (Wonders et al., 2009), increased antioxidant enzymes (Ascensão et 
al., 2005; Ashrafi, Roshan, & Mahjoub, 2012; Chicco, Hydock, Schneider, & 
Hayward, 2006; Kanter, Hamlin, Unverferth, Davis, & Merola, 1985), 
decreased lipid peroxidation (Marques-Alexio et al., 2014; Wonders, Hydock, 
Schneider, & Hayward, 2008), decreased cardiac DOX accumulation (Jensen 
et al., 2013), preservation of MHC composition (Hydock et al., 2011), and/or 
increasing the expression of multi-drug resistance protein (Krause et al., 2007; 
Parry & Hayward, in press).  
 Although a substantial amount of research has focused on the effects of 
endurance training, little attention has been placed on the effects of resistance 
training (RT) on DOX-induced cardiotoxicity.  Cancer rehabilitation programs 
have begun to incorporate RT due to the fact that this type of training can 
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result in significant improvements in muscular strength, aerobic capacity, and 
quality of life (Schwartz & Winters-Stone, 2009; Segal et al., 2003; Winters-
Stone et al., 2012).  Additionally, RT has been utilized as a rehabilitative 
therapy for heart failure, which may accompany DOX treatment, to counteract 
damaging peripheral side effects and improve quality of life (Alves, Nunes, 
Stefani, & Dal Lago, 2014).  To our knowledge, no studies have been 
conducted which examine the effects of RT on DOX-induced cardiotoxicity.  
Therefore, the purpose of this study was threefold: (a) to examine the effects 
of chronic RT prior to the administration of DOX on in vivo and ex vivo cardiac 
function in male Sprague Dawley rats, (b) to determine if any cardioprotective 
effects are a result of a reduction in lipid peroxidation, and (c) to determine if 




 The exercise modality implemented in this study mimicked resistance 
exercise training and consisted of a raised-caged model, which forces animals 
to assume an erect bipedal stance while feeding and drinking.  Following 12 
weeks of training, a bolus intraperitoneal 12.5 mg/kg DOX injection was 
administered 24 hours after trained animals had been placed into non-
elevated cages.  Control animals received a bolus intraperitoneal injection of 
0.9% saline (SAL).  Rats were sacrificed five days after DOX treatment, and 
cardiac function was analyzed both in vivo and ex vivo.  Following ex vivo 
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cardiac function assessment, the left ventricular (LV) was isolated and flash 
frozen in liquid nitrogen for biochemical analysis. 
Subjects 
 Ten-week-old male Sprague Dawley rats (N = 48) were randomly 
assigned to sedentary (SED) (n = 24) or RT (n = 24) groups in a temperature-
controlled facility with a 12:12-hour light-dark cycle.  Rats were provided 
standard rat chow and water ad libitum.  All protocols used for the study were 
approved by the University of Northern Colorado Institutional Animal Care and 
Use Committee and was in compliance with the Animal Welfare Act guidelines 
(see Appendix). 
Exercise Training 
 Animals that were randomly assigned to the RT group were placed in 
cages that allow for a progressive elevation of food and water, encouraging 
the animals to rise to a bipedal stance each time they eat and drink.  Cage 
height was raised to specified heights using specially designed plastic spacers 
that sat between the standard cage and the standard cage lid.  Placement of 
the spacers between the cage and the lid raises the food and water to the 
desired height.  This RT model has been shown to increase hind limb muscle 
mass and increased tibial cortical bone (Yao, Jee, Chen, Li, & Frost, 2001).  
On day one of the training protocol, cage height was raised from the standard 
20.32 cm to a height of 28 cm.  Cage height remained at 28 cm for one week.  
Following the first week, the height was raised by 2.5 cm.  From there, every 
third day cages were raised 2.5 cm until they reached the final height of 35.5 
cm.  This height was maintained for an additional 10 weeks for a total of 12 
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weeks of training.  Food and body weight were recorded daily, and adequate 
water consumption was confirmed for the first three weeks of training to 
ensure animals were able to reach both food and water.  Following the first 
three weeks of training, animals had their food measured and water monitored 
three days per week, and body weight was measured weekly.   
 At the completion of the 12-week training period, all plastic spacers 
were removed so that that all food and water returned to the standard cage 
height.  This was done to ensure that there were no effects of acute exercise 
on the observed dependent variables.  All animals remained in these standard 
cages for 24 hours prior to DOX treatment.  Following the 24-hour period, 
each animal was randomly assigned to one of four groups: SED+SAL (n = 9), 
SED+DOX (n = 15), RT+SAL (n = 9), and RT+DOX (n = 15).  The SAL groups 
received a bolus intraperitoneal 0.9% SAL injection, and the DOX groups 
received a bolus intraperitoneal 12.5 mg/kg DOX injection. 
 Various exercise modalities have been used to mimic RT.  These 
include tower climbing (Notomi et al., 2001), an erected bipedal stance 
exercise with a weighted vest (Westerlind et al., 1998), and an erected bipedal 
stance whole-body exercise (Yao et al., 2000).  Consistent findings have 
observed that an exercise modality that mimics RT can cause adaptation to 
bone, skeletal muscle, and cardiac muscle (Barauna, Rosa, Irigoyen, & de 
Oliveira, 2007; Duncan, Williams, & Lynch, 1998; Notomi et al., 2001).  There 
is no standard or set protocol for laboratory animal weight-bearing exercise 
modalities.  The range of total repetitions and total resistance varies greatly 
between studies.   
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 The RT model has been used by others (Mo et al., 2002; Rosa, Firth, 
Blair, Vickers, & Morel, 2011; Yao et al., 2000) and pilot studies in our 
laboratory.  Recently in our laboratory, the RT model has been associated with 
positive functional adaptations in skeletal muscle, which has also been 
observed following resistance protocols discussed previously.  These data, 
along with the pilot study, suggest that the exercise modality may be an 
effective model for exercise-induce cardiac adaptations. 
Assessment of Cardiac Function  
In Vivo Cardiac Function 
 In vivo cardiac function was analyzed five days after DOX treatment  
via echocardiography.  Animals were sedated with ketamine (40 mg/kg, 
intraperitoneal), and the anterior and left lateral thoracic regions were shaved.  
Transthoracic echocardiography was conducted on the sedated rats using a 
General Electric Vivid 7 ultrasound with a 10-MHz introperative transducer 
(Tustin, California).  Measurements of septal wall thickness during systole 
(SWs) and septal wall thickness during diastole (SWd), posterior wall 
thickness during systole (PWs) and posterior wall thickness during diastole 
(PWd), LV end systolic diameter (LVSd) and LV end diastolic diameter 
(LVDd), and fractional shortening (FS) were acquired by M-mode tracings of 
the LV obtained in a short axis view.  From an apical view using a pulsed-
wave Doppler, aortic and mitral blood flow echocardiographic images were 
obtained providing measurements of maximal flow velocity for both aortic and 
mitral valves.  All echocardiographic measurements were averaged from three 
consecutive cardiac cycles.  All M-mode and Doppler measurements were 
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made in accordance with guidelines established by the American Society of 
Echocardiography. 
Ex Vivo Cardiac Function 
 Ex vivo cardiac function was analyzed following echocardiography via 
an isolated working-heart model (ADInstruments, Colorado Springs, 
Colorado).  Each animal was anesthetized using an intraperitoneal injection of 
heparinized (500 U) sodium pentobarbital (50 mg/kg).  Following an absent tail 
pinch reflex, the heart was excised and placed into ice cold Krebs-Henseleit 
buffer (in mM: 120 NaCl, 5.9 KCl, 2.5 CaCl2, 1.2 MgCl, 25 NaHCO3, 17 
glucose, and 0.5 EDTA [ethylenediaminetetraacetic acid]) aerated with 95% 
O2 – 5% CO2.  Hearts were quickly cannulated by the ascending aorta and 
subjected to retrograde perfusion until all blood was cleared from the coronary 
vasculature.  The pulmonary vein was then cannulated, and blood flow was 
redirected from the aorta to the left atrium to initiate the working-heart model.  
Once stabilized, a microtip catheter pressure transducer (Millar Inc., Houston, 
Texas) was placed into the LV via the apex for determination of LV developed 
pressure (LVDP), LV maximum rate of developed pressure (+dP/dt), and 
minimum rate of developed pressure (-dP/dt).  Preload was set at 10 cmH2O 
and was maintained for all subsequent functional measurements.  Afterload 
was progressively increased every three to five minutes during data collection 
from 85 cmH2O, to 100 cmH2O, and to 115 cmH2O.  After data were collected 
at the three different afterloads, afterload was adjusted to 100 cmH2O, and 
hearts were paced at 240 beats per minute using electrodes attached to the 
cannula.  The LV functional data were collected and analyzed using a 
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PowerLab data acquisition system (ADInstruments).  Once data were 
collected, hearts were trimmed of connective tissue and fat and weighed.  The 
LVs were then isolated, flash frozen in liquid N2, and stored at – 80°C until 
subsequent biochemical analyses.  
Biochemical Analysis 
Lipid Peroxidation 
A commercially available assay kit (Bioxytech MDA-586, Oxis 
Research, Foster City, California) was used to measure malondialdehyde + 4-
hydroxyalkenal (MDA + 4-HAE) as an indicator of cellular lipid peroxidation.  
Tissues were homogenized in a radioimmunoprecipitation buffer for the assay.  
A 200 µL aliquot of each sample was added to a microcentrifuge tube followed 
by 650 µL of N-methyl-2-phenylindole in acetonitrile and briefly vortexed.  
Next, 150 µL of methanesulfonic acid was added, vortexed, and incubated at 
45°C for 60 minutes.  Samples were then centrifuged at 10,000 g for 10 
minutes.  The resulting supernatant was transferred to a cuvette and 
absorbency measured using a spectrophotometer at 586 nm.  The MDA + 4-
HAE was estimated from a standard curve.  All samples were assayed in 
duplicate, and any samples varying more than 5% were reassessed. 
Myosin Heavy Chain Analysis 
 Sample preparation was adapted from the method of Thomason, 
Baldwin, and Herrick (1986).  Approximately 100 mg of LV tissue was minced 
in a 2 mL glass tissue homogenizer with surgical scissors.  A 1:10 
weight/volume ratio of homogenization buffer (250 mM sucrose, 100 mM KCl, 
5 mM EDTA, and 20 mM Tris-Base, 4°C, pH 6.8) was added to the 
54 
 
homogenizer.  The sample was homogenized approximately five minutes 
using ScilogexD160 homogenizer (Rocky Hill, Connecticut).  Homogenates 
were centrifuged at 1,000 g for 10 minutes at 4°C and pellets collected and 
resuspended, with the same volume as homogenization buffer, in washing 
buffer (175 mM KCl, 0.5% Triton X-100, 2 mM EDTA and 20 mM Tris-Base, 
4°C, pH 6.8).  Samples were centrifuged again at 1,000g for 10 minutes at 
4°C.  The pellets were collected, resuspended with the same volume as 
previous washing buffer, and centrifuged at 1,000 g for 10 minutes at 4°C.  
The pellets were resuspended in the final resuspension buffer (150 mM KCl, 
and 20 mM Tris-Base, pH 7.0) at 1/12 of the previous volume.   
 Total protein concentration was determined using the Bradford protein 
assay method (Bradford, 1976).  Samples were then diluted to 2 mg/mL with 
the final resuspension buffer.  Twenty-five µL of each sample was further 
diluted to 0.125 mg/mL with 2x Laemmli sample buffer (20% glycerol, 16% 1M 
Tris [pH 6.8], 4% sodium dodecylsulfate [SDS], 1% β-mercaptoethanol, and 
0.2% bromophenol blue).  To denature the proteins, samples were boiled for 
two minutes and then placed on ice for another 10 minutes.  Following the 10 
minutes on ice, samples were loaded onto polyacrylamide gels. 
 The SDS polyacrylamide gel electrophoresis was used to determine 
MHC isoform expression.  The MHC gel composition used the modified 
method of Reiser and Kline (1998) from the original method of Talmadge and 
Roy (1993).  A 0.75 mm Snap-A-Gel cassette (Jule, Inc., Milford, Connecticut) 
was used to cast polyacrylamide gels.  The gel polymerization of separating 
gels (5% of 100% glycerol, 8% acrylamide-N,N'-methylene, 4% acrylamide-bis 
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[50:1], 0.2 M Tris-Base [pH 8.8], 0.1 M glycine, and 0.4% of 10% SDS) was 
initiated by adding 0.05% N,N,N',N'- tetramethylethylenediamine and 0.1% 
ammonium persulfate (10%).  After initiating the gel polymerization, the 
separating gel solution was pipetted into cassettes to approximately 1 cm 
below the height of the bottom of comb.  N-butonol was then pipetted to the 
top of the gel in order to flatten the separating gel during polymerization.  
Cassettes were then placed in the refrigerator for at least 60 minutes to allow 
the gel to polymerize.   
 Following polymerization of the separating gel, n-butanol was removed 
and cassettes rinsed five times with milli-pure water.  The polymerization of 
the stacking gel (5% of 100% glycerol, 4% acrylamide-bis [50:1], 70 mM Tris-
Base [pH 6.7], 4 mM EDTA and 0.4% of 10% SDS) was initiated by adding 
0.05% tetramethylethylenediamine and 0.1% ammonium persulfate (10%).  
The stacking gel solution was pipetted to the top of the separating gel and a 
10-lane comb was inserted (Jule, Inc.) into the stacking gel.  Cassettes were 
then placed in the refrigerator for at least 60 minutes to allow the stacking gel 
to polymerize.  
 Following polymerization of the stacking gel, combs were removed.  
Cassettes were placed into Novex Sure Lock cells (Invitrogen Corporation, 
Carlsbad, California).  Cassettes were locked and then the middle chamber 
was filled with upper running buffer (0.1 M Tris, 150 mM glycine, and 0.1% 
SDS).  Next, 7.5 µL of BenchMark™ protein standard (Invitrogen Corporation) 
was loaded in the first lane.  Following the protein standard, 7 µL of samples 
was loaded in the remaining lanes.  Lower running buffer (50 mM Tris, 75 mM 
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glycine, and 0.05% SDS) was poured into the outside chamber of the 
electrophoresis unit.   
 Electrophoresis was conducted at 100 V, 25 mA for approximately three 
hours or until the tracking dye was near the bottom of the gel.  The gels were 
then stained with Simply Blue safe stain for 60 minutes.  Gels were then 
placed in distilled water overnight.  The following day, gels were removed and 
placed between two transparency sheets and scanned.  Of the two bands on 
the gel, the slower migrating band was the α-MHC isoform and the faster was 
the β-MHC isoform.  The density of MHC protein bands was analyzed using 
ImageJ densitometry software (National Institutes of Health, Bethesda, 
Maryland).   
To quantify protein bands, the scanned gel was opened in ImageJ and 
converted to grayscale.  The brightness of the image was adjusted to isolate 
the protein bands.  Both bands were selected and then plotted to present a 
graphical depiction of band intensity.  The graphical depiction of band intensity 
showed two peaks.  The area under the two peaks was then marked off and 
selected.  After selecting each peak, values for the area under each band 
peak appeared in a window labeled “Results.”  The first value represented the 
α-MHC isoform and the second value represented the β-MHC isoform.  Both 
values were added together and the percentage of β-MHC was calculated. 
Statistical Analysis 
 Data were analyzed and presented using GraphPad Prism statistical 
software.  All data are expressed as mean ± standard deviation (M ± SD).  A 
two-way analysis of variance (ANOVA) was used to determine significant 
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difference due to the main effects (DOX and RT) and interaction.  Upon 
observation of a significant difference, a Tukey post-hoc pair-wise comparison 
was conducted to evaluate all pair-wise comparisons, which would identify 
differences between groups.  For all statistical analysis, significance is set at α 
= 0.05. 
Results 
The purpose of this study was threefold: (a) to examine the effects of 
chronic RT prior to the administration of DOX on in vivo and ex vivo cardiac 
function in male Sprague Dawley rats, (b) to determine if any cardioprotective 
effects are a result of a reduction in lipid peroxidation, and (c) to determine if 
any cardioprotective effects are a result of a preservation of the cardiac MHC 
isoform distribution.  
General Observations 
General observations are presented in Table 5.1.  Six animals died 
during the course of this experiment, making the total mortality rate 20% for 
DOX treated-animals.  The RT cut mortality in half, with SED+DOX having a 
mortality rate of 27% (4/15); whereas, the mortality rate for RT+DOX was 13% 
(2/15).  Animals in both SAL groups continued to gain body weight in the five 
days following injection; however, these gains were not significant.  A 2-way 
ANOVA on final body weight revealed a drug effect, F(1, 38) = 29.2, p < 
0.0001, with DOX-treated animals body weight significantly lower than SAL-
treated animals.  Five days following injection, body weight decreased 14% for 
both DOX groups, with no statistically significant difference between DOX 
groups.  A 2-way ANOVA on absolute heart mass revealed both a drug effect, 
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F(1,38) = 6.757, p = 0.0132, and activity effect, F(1, 38) = 11.33, p = 0.0018.  
Absolute heart mass was significantly higher in the RT+SAL group compared 
to SED+DOX.  Relative heart mass also showed a drug effect, 
F(1, 38)  = 5.448, p = 0.025, and activity effect, F(1, 38) = 18.87, p = 0.0001.  
Both RT groups had greater heart mass when compared to SED+SAL.  The 






























Relative heart mass 
(%) 






    9 
 
441 ± 37 
 
446 ± 36 
 
1.5 ± 0.18 
 




    9 
 
439 ± 57 
 
442 ± 54 
 
1.7 ± 0.17† 
 





  11 
 
447 ± 31 
 
386 ± 26 
 
1.4 ± 0.14 
 





  13 
 
446 ± 23 
 
384 ± 22 
 
1.6 ± 0.13 
 
0.40 ± 0.04* † 
 
Note. Data are represented as M ± SD.  SED = sedentary; RT = resistance 
trained; SAL = saline placebo; DOX = doxorubicin.  p < 0.05.  
*p < 0.05 versus SED+SAL. 








 Cardiac geometry (see Table 5.2) and blood flow velocities (see Table 
5.3) were measured by echocardiogram.  No statistically significant differences 
were seen between groups for SWd, PWs, PWd, LVDs, and FS.  Five days 
post injection, a 2-way ANOVA on SWs revealed a drug effect, 
F(1, 38) = 13.39, p = 0.0008.  A post hoc analysis determined that SED+DOX 
SWs was significantly thinner (p < 0.05) compared to both SED groups.  A 
drug effect, F(1, 38) = 14.45, p = 0.0005, was also observed on LVDd.  A post 
hoc analysis determined that SED+SAL LVDd was significantly greater (p < 
0.05) than RT+DOX.  Echocardiography Doppler images were used to analyze 
maximum blood flow through the aortic (A-Vmax) and mitral valves (M-Vmax).  
A 2-way ANOVA on A-Vmax revealed a drug effect, F(1, 38) = 79.25, p < 
0.0001, activity effect, F(1, 38) = 15.03, p = 0.0004, and interaction, F(1, 38) = 
13.42, p = 0.0008.  The M-Vmax also had a drug effect, F(1, 37) = 82.44, p < 
0.0001, activity effect, F(1, 37) = 7.002, p = 0.0119, and interaction, F(1, 37) = 
13.32, p = 0.008.  Significant decreases in A-Vmax and M-Vmax occurred with 
both DOX groups when compared to both SAL groups.  However, RT+DOX A-























































































































































Note. Data are represented as M ± SD.  SED = sedentary; RT = resistance 
trained; SAL = saline placebo; DOX = doxorubicin; SWs = septal wall 
thickness during systole; SWd = septal wall thickness during diastole; PWs = 
posterior wall thickness during systole; PWd = posterior wall thickness during 
diastole; LVDs = left ventricular end systolic diameter; LVDd = left ventricular 
end diastolic diameter; FS = fractional shortening. 
*p < 0.05 versus SED+DOX. 


















































68 ± 10* 
 
13 
         
A-V max 74 ± 15*† 9 31 ± 10 11 75 ± 10*† 9 57 ± 10* 13 
 
 
Note. Data are represented as M ± SD. SED = sedentary; RT = resistance 
trained; SAL = saline placebo; DOX = doxorubicin; M-Vmax = maximum blood 
flow through mitral valve; A-Vmax = maximum blood flow through aortic valve. 
*p < 0.05 versus SED+DOX. 




Isolated Perfused Working Heart 
 
 Following echocardiographic measurements, the cardiac variables 
ESP, EDP, LVDP, +dP/dt, -dP/dt, and heart rate were analyzed using an 
isolated working-heart apparatus.  Afterload was set at three different heights 
(85, 100, 115 cmH2O) during the analysis.  No statistically significant 
differences in heart rate and EDP were observed between the four groups at 
any of the afterloads.  Cardiac function at the three different afterloads is 
displayed in Figure 5.1.  At an afterload of 85 cmH2O, an interaction was 
observed for ESP, LVDP, and +dP/dt.  A post hoc analysis revealed that both 
SAL groups and RT+DOX had significantly higher (p < 0.05) ESP, LVDP, and 
+dP/dt when compared to SED+DOX.  Although RT+DOX was significantly 
higher than SED+DOX in ESP (34%) and LVDP (37%), RT+DOX ESP and 
LVDP were significantly lower than both SAL groups.  
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Figure 5.1. Unpaced ex vivo cardiac function.  (A) end systolic pressure, (B) end 
diastolic pressure, (C) left ventricular developed pressure, (D) maximal rate of 
developed pressure, and (E) maximal rate of pressure decline.  Values are M ± SD. 
Ψ significant differences between SED+SAL and SED+DOX 
# significant differences between RT+SAL and SED+DOX 
† significant differences between RT+DOX and SED+DOX 
* significant differences between SED+SAL and RT+DOX 




At an afterload of 100 cmH2O, an interaction was observed for ESP, 
LVDP, and +dP/dt.  A post hoc analysis revealed that both SAL groups and 
RT+DOX had significantly higher ESP, LVDP, and +dP/dt when compared to 
SED+DOX.  The SED+DOX –dP/dt was also significantly less when compared 
to SED+SAL.  Similar to an afterload of 85 cmH2O, RT+DOX was significantly 
higher than SED+DOX in ESP (44%) and LVDP (46%); however, the group 
was significantly lower when compared to both SAL groups.  The RT+DOX 
+dP/dt was also significantly lower when compared to SED+SAL.  
At an afterload of 115 cmH2O, an interaction was observed for ESP, 
LVDP, and +dP/dt.  A post hoc analysis revealed that both SAL groups and 
RT+DOX had significantly higher ESP, LVDP, +dP/dt, and –dP/dt when 
compared to SED+DOX.  Although RT+DOX was significantly higher than 
SED+DOX in ESP (44%), LVDP (46%), and +dP/dt (15%), RT+DOX ESP, 
LVDP, and +dP/dt were significantly lower when compared to both SAL 
groups.  
Paced cardiac function at an afterload of 100 cmH2O is displayed in 
Figure 5.2.  Following the collection of unpaced data, the afterload was placed 
at 100 cmH2O and LV pressure was measured at a standardized pace of 240 
beats/min.  An interaction was observed for ESP, LVDP, +dP/dt, and -dP/dt.  
Both SAL groups and RT+DOX had significantly higher ESP, LVDP, +dP/dt, 
and –dP/dt when compared to SED+DOX.  No significant differences were 
seen between RT+DOX and SAL groups for all variables. 
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Figure 5.2. Paced ex vivo cardiac function.  (A) end systolic pressure, (B) left 
ventricular developed pressure, (C) maximal rate of developed pressure, and 
(D) maximal rate of pressure decline.  Values are M ± SD. 




 As afterload increases, the normal physiological response is an 
increase in LV pressure.  Although not significant, increases (~ 5%) were 
observed for both SAL groups in ESP, LVDP, and +dP/dt as the afterload 
increased from 85 cmH2O to 115 cmH2O.  Both DOX groups showed little 
(< 2%) to no change in ESP, LVDP, +dP/dt, and –dP/dt as the afterload was 
increased from 85 cmH2O to 115 cmH2O. 
Biochemical Analysis 
 All data from biochemical analyses are presented in Table 5.4 and in 
Figures 5.3 and 5.4.  To provide an index of oxidative stress-induced damage 
in the myocardium, MDA + 4-HAE levels were analyzed.  A 2-way ANOVA on 
MDA + 4-HAE levels revealed a drug effect, F(1, 38) = 20.01, p < 0.0001.  A 
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post hoc analysis was performed to examine group differences.  No significant 
difference was seen within both DOX-treated and SAL-treated animals; 
however, RT+DOX MDA + 4-HAE levels were lower than SED+DOX. 
The MHC isoform distribution was examined to determine if an isoform 
shift played a protective role in DOX-induced cardiac dysfunction.  A 2-way 
ANOVA on percentage of β-MHC revealed a drug effect, F(1, 38) = 39.83, 
p < 0.001.  Additionally, an interaction effect was observed, F(1, 38) = 11.74, 
p = 0.0015.  A post hoc analysis was performed to examine group differences.  
The SED+DOX observed a significant increase in the percentage of β-MHC 
expression when compared to both SAL groups.  The RT+DOX relative β-
MHC expression was significantly higher than SED+SAL but not RT+SAL.  
The RT+DOX percentage of β-MHC was significantly lower than SED+DOX, 


















 M ± SD M ± SD M ± SD M ± SD 
 
MDA + 4-HAE (pmol/mg) 
 
679 ± 94*† 
 
896 ± 194 
 
673 ± 105*† 
 
829 ± 109 
 
β-MHC (%) 9 ± 3*† 36 ± 12 17 ± 8* 25 ± 9* 
 
Note. Data are represented as M ± SD.  SED = sedentary; RT = resistance trained; SAL = 
saline placebo; DOX = doxorubicin; MDA = malondialdehyde; HAE = hydroxyalkenal; MHC = 
myosin heavy chain. 
*p < 0.05 versus SED+DOX. 




















Figure 5.3. Myocardial lipid peroxidation in left ventricular homogenates. 
Values are M ± SD.  MDA + 4-HAE = malondialdehyde + 4-hydroxyalkenal. 
*significantly different than SED+SAL. 






















Figure 5.4. β-myosin heavy chain expression in left ventricular homogenates.  
Panel A is a representative scan, via ImageJ, from each group.  Panel B is the 
β-myosin heavy chain expression in the left ventricle.  Values are M ± SD.  
*significantly different than SED+DOX. 




With increased survival rates for cancer patients, it has become 
imperative to examine ways of reducing or attenuating cancer treatment-
related side effects.  The chemotherapeutic agent DOX is one of the most 
effective chemotherapeutic agents ever developed; however, its 





research has indicated that various types of exercise modalities can attenuate 
DOX-induced cardiotoxicity (Hydock et al., 2012; Hydock et al., 2008).  
Currently, cancer rehabilitation programs have begun to incorporate RT due to 
the fact that this type of training can result in significant improvements in 
muscular strength, aerobic capacity, and quality of life (Schwartz & Winters-
Stone, 2009; Segal et al., 2003; Winters-Stone et al., 2012).  The primary 
purpose of this study was to determine if chronic RT could attenuate the 
cardiac dysfunction induced by subsequent DOX treatment.  In addition, the 
effect of DOX and exercise training on cardiac lipid peroxidation and relative 
MHC isoform distribution was examined to provide a potential explanation for 
any observed changes in cardiac function.  Results indicate that DOX 
treatment caused cardiac dysfunction five days after its administration, prior 
chronic RT significantly attenuated this dysfunction, and the protective effects 
of this exercise modality were associated with a preservation of the MHC 
isoform distribution. 
Doxorubicin-Induced Cardiac Dysfunction 
 
The DOX treatment regimen used in the present study resulted in a 
significant impairment of cardiac function within five days of exposure, which is 
in agreement with previous investigations that examined cardiac function five 
days post DOX treatment (Hydock et al., 2011; Wonders et al., 2008).  These 
signs include significant reductions in mitral and aortic blood flow velocities as 
well as diminished systolic and diastolic function.  However, the DOX-induced 
alterations observed were significantly less in the RT+DOX group, indicating a 
cardioprotective effect of RT against DOX treatment. 
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Measuring ESP, LVDP, and +dP/dt can assess systolic function.  In 
agreement with previous studies, DOX treatment led to significant decreases 
in systolic function ( Chicco et al., 2006; Hydock et al., 2011).  Several 
mechanisms have been suggested to explain the depression of LV systolic 
function that occurs following DOX treatment including cardiomyocyte 
apoptosis (Childs, Phaneuf, Dirks, Phillips, & Leeuwenburgh, 2002), impaired 
Ca2+ handling (Asayama et al., 1995; Boucek, Dodd, Atkinson, Oquist, & 
Olson., 1997), and deleterious MHC shifts (Hydock et al., 2011). 
In the present study DOX-treated groups showed diminished diastolic 
function.  Significant differences were not observed in EDP between the four 
groups; however, an increase in afterload did affect diastolic function in the 
form of diminished –dP/dt for SED+DOX.  Although not significant, when 
increasing the afterload from 100 cmH2O to 115 cmH2O, SED+DOX –dP/dt 
decreased by 6%.  This indicates that at higher afterloads, myocardial 
relaxation was impaired.  Such an observation could have important 
ramifications for untrained cancer survivors who engage in infrequent 
exercise.  Exposure to moderately elevated afterload-type activities such as 
high-intensity aerobic or resistance exercise may impair diastolic function 
during the activity.  Several mechanisms could be involved in the impaired 
relaxation.  Impairment may have been caused by diminished Ca2+ uptake via 
sarcoendoplasmic reticulum ATPase 2 (SERCA2) as well as a decrease 
SERCA2 mRNA expression, which have been observed in previous studies 
(Arai et al., 2000; Hydock et al., 2011; Zhang et al., 2012).  Although the 
mechanisms are not fully understood, previous studies have suggested that 
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SERCA2 impairment could be a result of DOX-induced oxidative stress (Harris 
& Doroshow, 1985), which was in fact observed in the current study. 
Doxorubicin-Induced Cardiotoxicity 
 
 Possible mechanistic actions that could be responsible for DOX-
induced cardiac dysfunction include induction of apoptosis, excess generation 
of ROS, and unfavorable MHC shifts.  One purpose of the current study was to 
examine oxidative stress, as measured by MDA + 4-HAE, following DOX 
treatment.  DOX-treated groups showed a significant increase in oxidative 
stress compared to SAL, which is in agreement with previous studies (Chicco 
et al., 2006; Wonders et al., 2008).  The myocardium is highly aerobic; 
therefore, it requires a constant supply of adenosine triphosphate ATP by 
oxidative phosphorylation.  When DOX is administered it can lead to excess 
generation of ROS, mainly due to an increase in redox cycling at complex I in 
the electron transport chain (Marcillat, Zhang, & Davies, 1989).  As a result 
there becomes an imbalance between the antioxidant and pro-oxidant forces 
within and outside the cell, which is referred to as oxidative stress.  Increased 
oxidative stress may lead to a rise in intracellular Ca2+ due to impaired 
ryanodine receptor and SERCA2 function (Kim et al., 2006).  Furthermore, this 
altered Ca2+ homeostasis creates a cascade of events that can induce 
apoptosis (Sokolove & Shinaberry, 1988). 
 Another purpose of the study was to determine if unfavorable shifts in 
the MHC isoform distribution occurred following DOX treatment.  The DOX-
treated animals showed a significant increase in the relative expression of the 
β-MHC isoform and a significant decrease in the relative expression of the α-
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MHC isoform.  As stated previous, DOX administration can lead to oxidative 
stress.  This increased oxidative stress may also lead to an increased 
expression of β-MHC (Aragno et al., 2006).  The expression of both α-MHC 
and β-MHC plays an imperative role in cardiac function (Miyata, Minobe, 
Bristow, & Leinwand, 2000).  Cardiac α-MHC is the primary isoform in rat 
hearts (> 90%) and is associated with a greater contraction velocity and higher 
ATPase activity (Krenz et al., 2003).  Studies have indicated that DOX 
treatment can alter MHC distribution causing decreased expression of the α-
MHC isoform corresponding to an increase expression of the β-MHC isoform.  
This α to β shift significantly decreases cardiac contractility (Tardiff et al., 
2000).  In the present study, the cardiac dysfunction observed five days 
following DOX treatment might be a result of increased oxidative stress and 
altered MHC isoform distribution.  
Exercise-Induced Cardioprotection 
Despite the plethora of studies observing exercise-induced 
cardioprotection prior to DOX treatment, no studies have examined if RT prior 
to DOX treatment provides a cardioprotective effect.  The RT model used in 
the current study protected against DOX-induced septal wall thinning, LV 
mass reduction, mitral and aortic blood flow decrements, and cardiac 
dysfunction. 
From available evidence, it appears that multiple mechanisms may be 
simultaneously involved with the protective effects of chronic exercise against 
DOX-induced cardiotoxicity including, reduced DOX accumulation within the 
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cardiomyocyte (Jensen et al., 2013), attenuating unfavorable shifts in MHC 
(Hydock et al., 2011), and decreased oxidative stress (Chicco et al., 2005).   
Since it has been proposed that the primary mechanism of DOX-
induced cardiotoxicity involves increased oxidative stress, a purpose of the 
current study was to examine if the RT model used would attenuate DOX-
induced oxidative stress.  Contrary to the current study, Chicco et al. (2006) 
observed an attenuation of ethanol-induced cardiac lipid peroxidation following 
six weeks of RT.  The difference in results between the two studies may be 
due to the intensity of the exercise movement or differing degrees of oxidative 
stress provided by DOX versus ethanol.  In the previous study, animals 
performed exercise movements where the load lifted was started at 20% body 
weight and increased by 20% each week (Chicco et al., 2006), as compared to 
the current study in which animals exercised at a lower intensity with no 
external load.  However, the results of the current study are in agreement with 
a previous study in which low intensity exercise did not attenuate DOX-
induced oxidative stress although there was a preservation of cardiac function 
(Chicco et al., 2006). 
Another purpose of the study was to determine if cardioprotection is the 
result of preservation in relative MHC distribution.  Expression of the α-MHC 
isoform has been shown to increase following various types of exercise 
(Iemitsu et al., 2004; Jin et al., 2000).  A possible mechanism involved in this 
increased expression of the α-MHC isoform may be an upregulation of 
myocardial thyroid hormone receptors.  A study by Iemitsu et al. (2004) 
detected significant increases in myocardial thyroid hormone receptors α1, 
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correlating to an increase in α-MHC isoform expression following eight weeks 
of exercise.  In the current study, RT+DOX observed significantly less 
alteration in MHC isoform distribution compared to SED+DOX, indicating an 
exercise effect.  This is in agreement with a previous study indicating that 
exercise preconditioning preserved MHC isoform distribution following DOX 
treatment (Hydock et al., 2011).  This suggests that the cardioprotection 
observed in this study may be a result of preservation of the MHC isoform 
distribution. 
Although many studies observe consistent exercise-induced cardiac 
adaptations, characteristics of these adaptations differ.  Endurance training 
results in eccentric hypertrophy that can lead to enlargement of the LV 
chamber and increased LV dimensions.  The RT results in concentric 
hypertrophy, leading to a thickening of the LV wall and greater contractile 
force.  This is due to the type of circulatory overload that occurs with RT 
(Pluim, Zwinderman, van der Laarse, & van der Wall, 2000).  The present 
study using a RT model clearly demonstrated exercise-induced 
cardioprotection, similar to what has been seen with endurance training.  
However, the mechanisms surrounding the cardioprotection may differ.  A 
central theme of endurance training attenuation of DOX-induced cardiotoxicity 
is significant decreases in oxidative stress.  This was not observed in the 
present study.  This suggests that alternative mechanisms may be involved 




This is the first study to provide evidence suggesting that RT may 
preserve cardiac function and prevent deleterious MHC shifts following DOX 
treatment.  In the current study, DOX treatment resulted in impaired cardiac 
function, increased lipid peroxidation, and unfavorable shifts in the cardiac 
MHC isoform distribution.  However, 12 weeks of RT preconditioning resulted 
in a preservation of cardiac function.  The cardioprotective effects of exercise 
were associated with a preservation of the cardiac MHC isoform distribution.  
These findings suggest that chronic RT may be a beneficial counter 
measurement to DOX-induced cardiotoxicity.  Incorporating resistance training 
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